Ординатура / Офтальмология / Английские материалы / Clinical Ocular Pharmacology 5th edition_Bartlett, Jaanus_2008

Index

777

Imidazole derivative, 247, 248t, 249

Infection—cont’d

Injectable anesthetic, 86-87, 87t

Imipramine, 721t

canalicular, 433

Injection

Immune inflammation, acute and

of conjunctiva, 444-463. See also

conjunctival, 452

chronic, 237f

Conjunctivitis

epithelial microcysts and, 543

Immune system

corticosteroid increasing, 232

local infiltrative, 324

conjunctivitis and, 444

dacryoadenitis, 424, 424f

peribulbar, 49-50, 49b, 49f

in thyroid disease, 645

fungal. See Fungal infection

retrobulbar, 49, 49b

Immunization, varicella zoster, 396

meibomian gland, 386-387, 387f

steroid, for chalazion, 390

Immunocompromised patient, 396

of meibomian gland, 386-389, 387f

subconjunctival, 47-48, 49f

Immunoglobulin therapy for cicatricial

optic neuropathy in, 366-367

sub-Tenon’s, 49, 49f

pemphigoid, 468

of posterior lid margin, 386-389, 387f,

Injury. See Trauma

Immunologic disease, scleritis with,

388f

Innervation. See also Nerve entries

577b

postoperative, prevention of, 601

adrenergic, 113-114

Immunology, allergic, 245-249, 549-550

in scleritis, 584

cholinergic, 125, 126f

cell-mediated response in, 247

scleritis with, 577b

treatment options and, 247

uveitis with, 588b

296t

type I hypersensitivity in, 245-247,

viral. See Viral infection

Insert, artificial tear, 271-272, 272f

246f, 246t

Inferior rectus muscle, 649

Immunomodulatory agent, for tear

Infestation, eyelash, 397-399, 398

augmentation, 429

Infiltrating basal cell carcinoma, 403

Interferon, 595

Immunosuppression

Infiltrative event

Intermediate uveitis

in allergic disease, 550

in bacterial keratitis, 519-520, 519f, 519t

complications of, 596-597

in myasthenia gravis, 375-376

contact lens-related, 538-542, 540f, 544f

description of, 587

for necrotizing scleritis, 585

Infiltrative injection, local, 324

diagnosis of, 591-592

for ocular cicatricial pemphigoid, 468

Infiltrative keratitis, 540t

Internal limiting membrane, 306

for polyarteritis nodosa, 472

Infiltrative optic neuropathy, 366-367

in scleritis, 584, 585

Infiltrative thyroid-related orbitopathy,

Intolerance to apraclonidine, 155

for uveitis, 595-596

652

Intracameral administration, 50

Immunotherapy in myasthenia gravis, 376

Inflammation

Intracanalicular plug, 273t

Impaired vision from dilation, 76

acute and chronic immune, 237f

Imuran, 595

after cataract surgery, 602

739-740, 739t

Incision of eyelid, 410-412, 411f

canalicular, 433

tetracyclines and, 190

Inclusion conjunctivitis, 456-457, 457f

conjunctival, 439-440, 474-478

Indinavir, 207t

in phlyctenulosis, 474-475, 475f

and, 375

Indirect ophthalmoscopy, 676

in pinguecula, 476, 476f

Indocid, 236t

pterygium and, 477-478, 477f

Intraocular pressure

Indocin

in superior limbic

adverse effects of, 751t

keratoconjunctivitis, 475-476,

722b, 723t

for uveitis, 595

476f

atropine and, 129

Indocyanine green, 291-292, 291f

cyclosporine A as immunomodulator

cataract surgery and, 603, 608

Indocyanine green angiography, 619-620

of, 236-242

Indomethacin, 102t

dry eye and, 264-265

drugs for. See Hypotensive drug

adverse effects of

of eyelid, 568, 570

hyphema and, 692

on cornea, 709-710

in chalazion, 390-391

measurement of, 671-674, 673b

retinal, 730

in external hordeolum, 389, 389f

in retinal vein occlusion, 634

brimonidine and, 235

in internal hordeolum, 389-390, 390f

tropicamide and, 135-136

formulations of, 236t

lacrimal gland and, 416

for uveitis, 595

postoperative, 228

Intravitreal injection, 50-51, 51f

Infant

in staphylococcal blepharitis, 383f

of corticosteroid implant, 309

conjunctival flora in, 438

in thyroid disease, 645, 648

cycloplegic refraction in, 343, 344

in uveitis, 588

epiphora in, 429-430

Inflammatory cytokine, 265

Invirase, 207t

esotropia in, 667-668

Inflammatory glaucoma, steroid-

Iontophoresis, 94

maternal myasthenia gravis and, 373

induced, 596

Ipratropium bromide, 718

pupil dilation in, 334-335

Inflammatory response, 233

Iproclozide, 690t

Infection. See also Antibacterial drug;

Infliximab

Iproniazid, 690t

Bacterial entries; specific infection

adverse effects of, 716t, 717

Iridectomy, 336-337, 337f

of anterior lid margin, 381-386, 383f,

for uveitis, 595

385f, 386f

Informed consent

rimexolone for, 229

of anterior margin of eyelid, 382-384,

alternatives to drug therapy and, 69

Iris

383f

disclosure in, 65-66, 66b

angiography of, 287-288

bacteria causing, 177

documentation in, 70

in anterior uveitis, 590

Index

779

Lagophthalmos, 406

Levobunolol, 150-151

Local anesthetic—cont’d

nocturnal, 508

formulations of, 146t

toxicity as, 90-91, 90f, 91f

Lamellar endothelial keratoplasty, 490f

for glaucoma, 689t

structure features as, 86f

Lamellar laceration, 502-504-502f, 503f,

Levocabastine, 254t, 255, 551t

topical, 87-90, 88t, 89f

504f

in seasonal conjunctivitis, 560

Lamivudine, 206t

Levodopa, for blepharospasm, 377

326f

Landmark in gonioscopy, 333f

Levofloxacin, 194t, 195

Langerhans cell, 438

for conjunctivitis, 449

conjunctivitis, 563

Laser, stromal puncture with, 506

formulations of, 186t

Lodine, 751t

Laser imaging in glaucoma, 679, 679t

for infectious conjunctivitis, 446

Lodoxamide, 255, 256t, 257, 553t

Laser in situ keratomileusis

in preseptal cellulitis, 391

in seasonal conjunctivitis, 561

cyclosporine A for, 265

Lexiva, 207t

dry eye after, 265

Liability, product, 78

Lomefloxacin, 194t

Laser surgery

Licorice, 741

iridectomy, 336-337, 337f

adverse effects of, 759t

Lopinavir, 207t

Laser surgery

Lid margin, 425

Loratadine, 250, 252t, 253, 552t

acetazolamide and, 161

Lid scrub, 45, 46t

for seasonal conjunctivitis, 561

apraclonidine and, 155

Lidocaine

Lotemax, 555t

brimonidine and, 157

injectable, 87t

Loteprednol, 554t

LASIK

intracameral administration of, 50

as antiallergy drug, 259

cyclosporine A for, 242

subcutaneous injection of, 327f

clinical uses of, 228-229

dry eye after, 265

Light reaction in anisocoria, 349, 351f

contact lens-related papillary

Latanoprost, 139-143, 687-688, 687t

Light sensitivity after pupil dilation, 339

conjunctivitis and, 564

brimonidine with, 156

Limbal conjunctival substantia propria,

for corneal ulcers, 525

clinical uses of, 140-141

438

in episcleritis, 578

contraindications to, 142

Limbal keratoconjunctivitis

formulations of, 227t

pharmacology of, 139-140, 140f

superior, 475-476, 476f

in seasonal conjunctivitis, 561

side effects of, 141-143, 141b, 142f

vernal, 565

Lateral tarsorrhaphy, 427-428

Limbal phlyctenule, 474

keratitis, 534

Lattice type dystrophy, 485t

Limbal stem cell transplantation, 468-469

Lovastatin, 749t

Lavage for foreign body, 479f

Line

Low vision, 13-14, 13f-14f

Law, Fick’s, 25-26

Arlt’s, 458, 458f

Lubricant

Lax eyelid syndrome, 406-408, 407f

fingerprint, 486

in episcleritis, 578

Legal issue, 63-81

Vogt’s, 490

in exposure keratopathy, 508

documentation as, 78-79, 78b

Lineate incision of eyelid, 410-412, 411f

Lucentis, 35t, 306-307

drug use complications as, 75-78

Lipid layer of tear film, 263, 264f, 416

Lumigan, 687-688, 687t

diagnostic, 75-76

evaluation of, 421

Lumiracoxib, 751t

therapeutic, 76-78

Lipid monolayer of years, 17

Lutein for age-related macular

informed consent as, 65-70

Lipitor, 749t

degeneration, 636

alternatives to drug therapy and, 69

Lissamine green, 290-291, 291f, 422

Lyme disease

disclosure in, 65-70, 66b, 68f, 69f

in exposure keratopathy, 508f

conjunctivitis and, 459

documentation in, 70

Lithium

interstitial keratitis in, 516t

misdiagnosis as, 73-75, 73t

adverse effects of, 757t

Lymphatic system, in conjunctival

practice laws as, 63-70

eye movement caused by, 719

inflammation, 440

certification as, 63-64

Liver

M

comanagement as, 64-65, 64b

local anesthetic precautions and, 93

registration as, 64

penicillin effects on, 182

Macrolide

standards of care as, 72-73

Livostin, 254t, 551t

azithromycin as, 192

Lens

in seasonal conjunctivitis, 560

clarithromycin as, 191-192

adverse drug effects on, 7t, 704-711,

Local anesthetic, 85-95, 323-324. See also

erythromycin as, 191

704t

Anesthesia

side effects of, 192

in anterior uveitis, 591

classification of, 86b

Macugen, 35t, 305-306

contact. See Contact lens

contraindications to, 92-94, 94f

Macular disease, 632-639

intraocular, postoperative dislocation

pharmacologic properties of

age-related degeneration

of, 612-613, 613f

mechanism of, 85-86

anecortave for, 310

spectacle, 42, 42f

physiochemical characteristics of, 85

diagnosis of, 635-636

structure of, 23

structure features as, 85

Leprosy, interstitial keratitis in, 516t

self-administration of, 93-94

299-300, 636-637

Leukopenia, 193-194

side effects of, 90-92

etiology of, 635, 635f, 636f

Leukotriene, 233

hypersensitivity as, 91-92, 92f

Levitra, 730

prevention of, 92

for, 51

adverse effects of, 749t

psychomotor, 92

management of, 636-639

780

Index

Macular disease—cont’d

Meibomian gland

Mild pain

pegaptanib for, 306

anatomy and physiology of, 415-416

in child, 109

photodynamic therapy in, 304

evaluation of, 423, 423f

in elderly, 110

ranibizumab for, 307

tear film and, 263

Milia, 401, 401f

retinal disease and, 635-639, 635f,

Meibomianitis, 386-388, 387f

Mineral supplement, 295-301. See also

636f

in atopic keratoconjunctivitis, 567

Vitamin and mineral

rostaporfin for, 305

dry eye and, 425

supplementation

triamcinolone acetonide for, 308

tetracyclines for, 190

Mini-Tip culturette, 441

vascular endothelial growth factor

Meige’s syndrome, 377

Minocycline

and, 305

Mellaril, 756t

adverse effects of, 754t

zinc and, 208

Membrane

on optic nerve, 739-740

cystoid edema, 363f, 632-635, 633f

in adenoviral conjunctivitis, 452

for meibomian gland infection, 387

after cataract surgery, 613-614, 614f

anterior basement, 486-488, 487f

vestibular toxicity of, 190-191

ketorolac for, 236

in bacterial conjunctivitis, 446

Miosis

latanoprost and, 142-143

conjunctival, 439

phenylephrine and, 116

nonsteroidal anti-inflammatory

Descemet’s, 483

reversal of, 120-121, 120f, 121f

drugs and, 234-235

Membrane squamous metaplasia, 271

Miotic

dystrophy in, 484t

Mepivacaine, injectable, 87t

for accommodative esotropia, 665

Macular Photocoagulation Study, 291, 637

Mercurial

adverse effects of, 719

Madarosis, 383f

in artificial tears, 270

after pupil dilation, 339

Magnetic resonance imaging in thyroid

effects of, 30

complications of, 77

disease, 650-651, 651f

Meretoja syndrome, 485t

pilocarpine and, 168-170, 168t, 171b

Malignant tumor of eyelid, 402t

Metabolic acidosis, 162

side effects of, 169b

basal cell carcinoma as, 403-404, 403f,

Metabolic disease, scleritis

Misdiagnosis

404f

with, 577b

negligence and, 70

signs of, 402b

Metallic corneal foreign body, 498f

of open-angle glaucoma, 73-74

squamous cell carcinoma as, 404-405,

Metalloproteinase inhibitor, 190

of retinal detachment, 74-75

405f

Metaplasia, membrane squamous, 271

therapeutic drug use related to, 77-78

Malnutrition, conjunctiva and, 478

Methazolamide, 163-164

of tumor, 74

Mannitol in glaucoma, 694

adverse effects of, 755t

Mite. See Demodex entries

Mannitol salt agar, 441

pharmacokinetic properties of, 161t

Mitomycin

Map, anterior basement membrane

Methicillin, 180t

for pterygia, 478

dystrophy and, 486

Methicillin-resistant penicillin, 181

reduced tear production and, 715

Marfan’s syndrome, 335

Methicillin-resistant Staphylococcus

in vernal keratoconjunctivitis, 566

Marijuana, lacrimation and, 715

aureus, 185, 449

Mnemonic

MARINA trial, 307, 308, 638

Methicillin-resistant Staphylococcus

CARVES, 677

Massage in congenital epiphora, 430, 430f

epidermidis, 185

NOSPECS, 645-646, 646t

Mast cell, 549

Methimazole, 652-653

Moclobemide, 690t

Mast cell activation, 246f

Methotrexate

Model of surface inflammation, 240

Mast cell stabilizer, 255, 256t, 257, 550,

adverse effects of, 754t

Moderate pain

552t, 553t, 558t-559t

for polyarteritis nodosa, 472

in child, 109

contact lens-related papillary

for psoriasis, 465

in elderly, 110

conjunctivitis and, 564

8-Methoxypsoralen

Moisture Eyes, 267t

in seasonal conjunctivitis, 560-561

adverse effect of, on lens, 704t

Moisture Eyes PM, 272t

in vernal keratoconjunctivitis, 566

adverse effects of, 757t

Moisture Liquigel, 267t

Mast cell-antihistamine combination,

adverse effects of, on cornea, 711

Moll cyst of eyelid, 401, 401f

257, 258t, 259

Methylene blue, 292

Molluscum contagiosum

Maxipime, 184t

Methylphenidate, 718

conjunctivitis and, 458-459, 458f

Maxitrol, 464

Methylprednisolone, 657

of eyelid, 396-397, 396f

Mebendazole, 630

Metipranolol, 152

Monitoring, 3-4

Medennium SmartPLUG polymer, 273t

formulations of, 146t

Monoamine oxidase inhibitor

Medial canthus technique, 346

for glaucoma, 689t

contraindications to, 690, 690t

Medical history, importance of, 4t, 5

MetroGel, 464

phenylephrine and, 117

Medicamentosa, 513

Metronidazole, 464

Monoclonal antibody for retinal disease,

Medication history, importance of, 4t, 5-6

Mezlocillin, 180t

306-308

Medrysone

Micafungin, 208, 210t, 212t, 213t,

Monocular trial glaucoma, 686-687

clinical uses of, 228

214-215

Moraxella

formulations of, 227t

Miconazole, 208, 211t, 213, 213t

azithromycin for, 192

ocular hypertension and, 231

Microbial keratitis, 540t

conjunctivitis and, 459

MEDWatch form, 742f-743f

Microcyst, epithelial, 542-545, 544f

corneal ulcer and, 521t

Meesmann’s dystrophy, 484t

Microflora, 184

Morpheaform basal cell carcinoma, 403

Mefoxin, 184t

Microvillus, 263, 264

Morphine, 104

Index

781

Mortality, atropine causing, 129

Mydriacyl Ophthalmic, 127t

Natamycin, 208, 209t, 211t, 213t

Motion sickness, 130

Mydriasis

for Acanthamoeba, 216t

Motrin, 102t

atropine causing, 129

in fungal keratitis, 536

adverse effects of, 751t

corticosteroid causing, 232

National Registry of Drug-Induced

Mouth, dry

drugs causing, 22

Ocular Side Effects, 116

apraclonidine causing, 155

jimson weed, 361-362

N-chlorotaurine, 526

brimonidine and, 157

unilateral fixed and dilated pupil in,

Nd:YAG laser

Movement, eye, drugs causing, 719-720,

361-362, 361f, 362, 362f

719t

Mydriatic agent, 114-119

stromal puncture with, 506

Moxifloxacin, 194t, 195

adrenergic innervation and, 113-114

in burn injury, 510

adverse effects of, 718-719, 718b

for conjunctivitis, 449

in angle-closure glaucoma, 693

625f, 625t

for corneal ulcers, 523-524

angle-closure glaucoma induced by,

for foreign body, 500

335-336

pathogens susceptible to, 442t

cocaine as, 119

in recurrent corneal erosion, 505

complications of, 75-76

621f, 622f, 622t

in thyroid-related orbitopathy, 656

guidelines for, 333-334

for toxic keratitis, 514

hydroxyamphetamine as, 117-119,

624-626, 625f, 625t

Mucin layer of tear film, 264, 416-417

118f

Mucoadhesive performance of

phenylephrine as, 114-117

Necrotizing scleritis, 580

polymer, 32t

clinical uses of, 114-116

immunosuppression in, 585

Mucocyst, 555t

contraindications to, 117

without inflammation, 579

Mucoid cyst of eyelid, 401, 401f

pharmacology of, 114

Nedocromil, 255, 256t, 257, 553t

Mucolytic agent, 429

side effects of, 116-117

in artificial tears, 271

spray as, 43, 43f

499f

Mucous fishing syndrome, 426, 426f, 480

for uveitis, 594

Negligence, 70-72

Mucous membrane disorder of

Mydriolytic agent, 119-121, 120f, 121f

proof of, 71-72

conjunctiva, 467-470

adrenergic innervation and, 113-114

Neisseria gonorrhoeae

cicatricial pemphigoid and, 467-469,

Myobloc, 379

cephalosporin for, 183

467f, 468f

Myokymia, 407-408

conjunctival culture for, 441

in erythema multiforme major, 469-470

Myopia

conjunctivitis and, 447, 448

in Stevens-Johnson syndrome, 469-470

acetazolamide causing, 162

hyperacute, 449-451, 450f

in toxic epidermal necrolysis, 469-470

atropine for, 128

infections caused by, 177, 178t

Mucous plaque keratitis, 532f, 533

cycloplegic refraction in, 343

penicillin for, 181

Mucus fishing syndrome, 480

drugs causing, 720-722, 720b, 721f

Neisseria meningitidis, 450

Müller’s muscle, 353

sulfonamides and, 194

Nelfinavir, 207t

Multi-drug therapy, 703

N

Mumps, 516t

Munchausen syndrome

N-3 fatty acid, 276

laser

conjunctivitis in, 480

NaEDTA chelation, 495

ocular, 480

Nafcillin, 180t

stromal puncture with, 506

Muscarinic receptor, 125-126

Na+-K+-adenosine triphosphatase,

Neomycin, 187-188

Muscle

carbonic anhydrase inhibitor

for conjunctivitis, 447-448

extraocular

and, 159

of Acanthamoeba, 216t

adverse drug effects on, 719-720,

Naphazoline, 247, 248t, 249, 254t

formulations of, 187t

719t

in episcleritis, 578

in thyroid disease, 645, 656

Naphcon, 248t

steroids with, 188t

in myasthenia gravis, 373, 374

Naphcon-A, 254t, 551t

Myambutol, adverse effects of, 753t

Naprosyn, 102t

464

Myasthenia gravis, 372-376

adverse effects of, 751t

Neonate

clinical features of, 373-374, 373f

for uveitis, 595

gonococcal ophthalmia in,

diagnosis of, 373

Naproxen

tetracyclines for, 190

epidemiology of, 373

adverse effects of, 751t

phenylephrine and, 117

etiology of, 372-373

for child, 109t

pupil dilation in, 334-335

management of, 375-376

formulation of, 102t

Neoral, 595

pharmacologic evaluation of, 374

for uveitis, 595

Neostigmine, 374

testing for, 374-375, 375f

Narrow angle

Neovascular glaucoma, 693

Mycamine, 210t

after iridectomy, 336-337, 337f

Neovascularization

Mycophenolate

pupil dilation in, 335-336

in myasthenia gravis, 376

Nasal field defect, 682f-683f

contact lens-related, 541f

for uveitis, 595

Nasolacrimal duct, 417-418

in retinal disease, 619-620

Mycoplasma pneumoniae, 192

in congenital epiphora, 429-430

in uveitis, 588

784

Index

Patient history, importance of, 4-6, 4t

Pharmacokinetics—cont’d

PDE-5, 730

drug development and, 36

PDE-6, 730

drug properties affecting, 27-36

Peaked pupil, 609-610, 610f

active ingredients as, 28, 29t

Pediatric patient. See Child

bioavailability as, 27-28, 27f

Pediculocidal agent, 399

osmolarity as, 28

Pediculus humanus, 397-399

preservatives as, 28, 30-31

Pegaptanib, 305-306

stability as, 28

for age-related macular degeneration,

vehicles as, 31-34, 31b, 32t, 33f

638

drug release systems as, 34, 35t, 36

Pemirolast, 255, 256t, 257, 553t

of iris, 22

Pemphigoid, cicatricial, 467-469, 467f,

of ocular structures, 17-37

468f

prodrugs and, 27

Penalization, atropine, 664-665, 665b

of retina and optic nerve, 24-25, 24t

Penetrating corneal injury, 502-504-502f,

of sclera and cornea, 19-22, 20f, 21f, 21t

503f, 504f

of tear film, 17-19, 18f, 19f

Penetrating keratoplasty

of vitreous humor, 23-24

for Acanthamoeba keratitis, 538

Pharmacologic blockade, 361

in Fuchs’ dystrophy, 489f

Pharmacotherapy, 3-15

in fungal keratitis, 536

adverse reactions to

in recurrent corneal erosion, 506-507

ocular, 7-8, 7t, 8f

in trauma, 503-504

systemic, 8-9, 9t

Penetration, drug, scleral, 20

in child, 11-12, 11t

Penicillin, 179-183

determining contraindications to

antipseudomonal, 180t, 182

clinical examination in, 6-7

clinical uses of, 181-182

patient history in, 4-6, 4t

contraindications to, 182-183

in difficulty swallowing, 14

extended spectra of activity in, 180t,

in elderly patient, 12-13

181-182

incidence of, 5

for gram-positive bacteria, 180t, 181

initiating, 3-4

for internal hordeolum, 390

monitoring, 3-4

pharmacology of, 179

in pregnancy, 9-11, 10f

in preseptal cellulitis, 391

in visually handicapped patient, 13-

resistant to penicillinase, 180t, 181

14, 13f-14f

side effects of, 182

Pharyngoconjunctival fever, 452, 453t

Penicillinase, 181

epidemic keratoconjunctivitis versus,

Penicillin-resistant Streptococcus

527

pneumoniae, 185

Phenelzine, 690t

Penicillum, 534

Phenergan, 251t

Pentamidine, 215

Pheniramine, 254t, 551t

Pentazocine, 104t

side effects of, 255

Pentolair, 127t

Pheniramine-naphazoline, 254

Peptostreptococcus, 391

Phenol red thread test, 421

Perennial conjunctivitis, 550, 560-561 560f

Phenothiazine

Perforation, globe, 581

accommodation disturbance

Peribulbar anesthesia, 604

and, 721

Peribulbar injection, 49-50, 49f

adverse effects of, 756t

Perimetric test of visual function, 680t

Phenylephrine, 114-117, 247, 248t, 249

Periocular steroid

in angle-closure glaucoma, 693

for uveitis, 594, 596-597

clinical uses of, 114-116

Periorbital cellulitis, 391-393, 391t, 392f

contraindications to, 117

Periorbital dermatosis, 568

for corneal abrasion, 497

Peripapillary atrophy, 678, 678f

dapiprazole and, 120

Peripheral ulcer, 540t

in episcleritis, 578

Petrolatum ointment, 399

hydroxyamphetamine and, 118

pH of tears, 17

for infant or child, 334

Pharmacokinetics

pharmacology of, 114

of aqueous body, 23

side effects of, 116-117

blood supply and, 25

in systemic disease, 335

of ciliary body, 23

Phlyctenular keratoconjunctivitis,

compartment theory and, 25-27, 26f

517-518, 518f

of crystalline lens, 23

tetracyclines for, 190

786

Index

Prostaglandin analogue—cont’d

Ptosis—cont’d

Ranibizumab, 306-307

latanoprost, 139-143, 140b, 140f,

in myasthenia gravis, 373, 373f

for age-related macular degeneration,

141b, 142f, 145f

Pulmonary function, betaxolol and, 151

638, 639

travoprost, 143-144, 145f

Punctal dilation, 432f

Rapidly progressive herpetic retinal

nonsteroidal anti-inflammatory drugs

Punctal disorder, 432-433

necrosis, 624-626, 625f, 625t

and, 235

Punctal plug, 428f

Rash

Prostaglandin compound, 145

anesthesia for, 323

penicillin causing, 182

Protease inhibitor, 206t-207t

Punctate bacterial keratitis, superficial,

sulfonamides causing, 194

Protein

514-515, 514f

RCE. See Recurrent corneal erosion

methazolamide and, 163

Punctate epithelial corneal erosion, 143

Reasonable patient standard, 66, 66b

in uveitis, 588

Punctate keratitis,Thygeson’s

Rebound miosis, 116

Protein kinase C, 311-312

superficial, 241-242

Recall, documentation of, 79

Protein synthesis, antibacterial drug

Punctate keratopathy, 514

Receptor

affecting, 187-193

Puncture, anterior stromal, 506

cholinergic, 125

amikacin as, 190

in recurrent corneal erosion, 507

FP, 139

aminoglycosides as, 187-190

Pupil. See also Mydriatic agent

histamine, 245-247, 246f, 246t

chloramphenicol as, 192-193

in anisocoria, 349

muscarinic, 125-126

gentamicin as, 188

in anterior uveitis, 590

Receptor-mediated inflammatory

macrolides as, 191-192

cholinergic innervation and, 125, 126f

process, 264

neomycin as, 187-188

dilation of, 329-341. See also Dilation

Receptor-mediated inflammatory

tetracyclines as, 190-191, 190t

of pupil

response, 264

tobramycin as, 189

complications of, 75-76

Record of patient care, 79

Proteus

disclosure of risks of, 67-69,

Recreational drug, 703

conjunctivitis and, 448, 451

68f, 69f

Recurrent corneal erosion, 486, 487,

infections caused by, 177

mydriatic agent for, 114-119. See

504-507, 504f, 507f

Protoptic, 555t, 570

also Mydriatic agent

Recurrent herpes simplex keratitis, 528

Protozoan infection, 215, 216t, 217

examination of, 6

Red eye, contact lens-related, 540t

Pruritus, 571

postoperative distortion of, 609-610,

Redness in anterior uveitis, 590

Pseudomembrane

610f

Referral, 79

in adenoviral conjunctivitis, 452

unilateral fixed and dilated, 360-362

Refraction

in epidemic keratoconjunctivitis, 525

adrenergic mydriasis causing, 362

atropine and, 128

in inflammation, 439

anticholinergic mydriasis causing,

cycloplegic, 6, 343-348. See also

Pseudomembranous colitis, antibiotic-

361-362, 361f, 362f

Cycloplegic refraction

associated, 184

iris injury causing, 362

Refractive error, 345

Pseudomembranous conjunctivitis, 447

third nerve palsy causing, 360-361,

Refractive surgery, 265

Pseudomonas, 448

361f

Refresh, 267t

Pseudomonas aeruginosa

Pupillary block glaucoma, 67

Refresh Endura, 427t

aminoglycosides for, 187

Purified protein derivative, in uveitis, 598

Refresh PM, 272t

cephalosporin for, 183

Purite, 156, 270

Refresh products, 427t

in conjunctival flora, 438

PUVA, for psoriasis, 466

Regional nerve block, 323-324, 324f

corneal ulcer and, 520, 521t, 522f

PVP, 269

Registration, 64

infections caused by, 177, 178t

Pyrethrin, 399

Regulatory issues for prescription

ophthalmia neonatorum and, 462

Pyridostigmine bromide, 375

writing, 54-58, 54f, 55t, 58b

penicillin for, 182

Pyrimethamine, 193-194

Reis-Bücklers dystrophy, 484t

Pseudophakia, 605t. See also Cataract

for toxoplasmosis, 627-628

Reiter’s syndrome, 472-474, 473f

surgery

Pyrimidine, 205, 208

Release, drug, 34, 36

Pseudophakic cystoid macular edema,

Q

Relief decongestant, 248t

613-614, 614f, 633

Remicade, 595

Pseudotumor cerebri

Quality of care, 53

Renal disorder

drug-induced, 739

Quality of life in glaucoma, 695-696

contraindications related to, 5

optic neuropathy in, 365f, 366

Quaternary ammonium compound,

dorzolamide and, 165

tetracyclines and, 190

270

in polyarteritis nodosa, 471-472

Psoralen, 704t

Quetiapine, 757t

Renal function

Psoralen ultraviolet A irradiation, for

Quinine, 750t

acetazolamide and, 163

psoriasis, 466

retinal, 734

carbonic anhydrase inhibitor

Psoriasis vulgaris, 465-466

R

and, 162

Psychomotor reaction to local

cephalosporins and, 184-185

anesthetic, 92

Race

NSAIDs and, 103

Pterygium, 477-478, 477f

acetazolamide and, 163

Rescriptor, 206t

Ptosis

uveitis and, 589

Residual accommodation

botulinum toxin and, 667

Radioactive iodine uptake test, 644

cycloplegics and, 346, 347

corticosteroid causing, 232

Raeder’s syndrome, 355

tropicamide and, 133-134